Biswal S, Mehta R. Cutaneous adverse reactions of chemotherapy in cancer patients: A clinicoepidemiological study. Indian J Dermatol. 2018;63:41.

Article  PubMed  PubMed Central  Google Scholar 

Salah S, Kerob D, Pages Laurent C, Lacouture M, Sibaud V. Evaluation of anticancer therapy-related dermatologic adverse events: Insights from Food and Drug Administration’s Adverse Event Reporting System dataset. J Am Acad Dermatol. 2024;91:863–71.

Article  CAS  PubMed  Google Scholar 

Deutsch A, Leboeuf NR, Lacouture ME, McLellan BN. Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy. American Society of Clinical Oncology Educational Book; 2020. p. 485–500.

Google Scholar 

Bolognia JL, Cooper DL, Glusac EJ. Toxic erythema of chemotherapy: A useful clinical term. J Am Acad Dermatol. 2008;59:524–9.

Article  PubMed  Google Scholar 

Hunjan MK, Nowsheen S, Ramos-Rodriguez AJ, Hashmi SK, Bridges AG, Lehman JS, El-Azhary R. Clinical and histopathological spectrum of toxic erythema of chemotherapy in patients who have undergone allogeneic hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther. 2019;12:19–25.

Article  CAS  PubMed  Google Scholar 

Cole DW, Menge TD, Lowe L, Chan MP, Bresler SC. Clinical and Histopathologic Spectrum of Toxic Erythema of Chemotherapy: A Series of 56 Cases From a Single Institution. Am J Dermatopathol. 2024;46:337–45.

Article  PubMed  Google Scholar 

Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: A review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol. 2014;71:787–94.

Article  PubMed  Google Scholar 

Smith SM, Milam PB, Fabbro SK, Gru AA, Kaffenberger BH. Malignant intertrigo: A subset of toxic erythema of chemotherapy requiring recognition. JAAD Case Rep. 2016;2:476–81.

Article  PubMed  PubMed Central  Google Scholar 

Lu A, Endicott A, Tan SY, Klufas DM, Merrill E, Arakaki R, LeBoit PE, Fox L, Haemel A. Toxic epidermal necrolysis-like toxic erythema of chemotherapy: 2 illustrative cases. JAAD Case Rep. 2021;15:56–9.

Article  PubMed  PubMed Central  Google Scholar 

Horn TD. Observations and Proposed Mechanism of N,N′,N″-Triethylenethiophosphoramide (Thiotepa)-Induced Hyperpigmentation. Arch Dermatol. 1989;125:524.

Article  CAS  PubMed  Google Scholar 

Zhang B, Bolognia J, Marks P, Podoltsev N. Enhanced skin toxicity associated with the combination of clofarabine plus cytarabine for the treatment of acute leukemia. Cancer Chemother Pharmacol. 2014;74:303–7.

Article  CAS  PubMed  Google Scholar 

Brockow K. Detection of drug-specific immunoglobulin E (IgE) and acute mediator release for the diagnosis of immediate drug hypersensitivity reactions. J Immunol Methods. 2021;496:113101.

Article  CAS  PubMed  Google Scholar 

Pichler WJ. Delayed Drug Hypersensitivity Reactions. Ann Intern Med. 2003;139:683–93.

Article  CAS  PubMed  Google Scholar 

Nikolaou V, Syrigos K, Saif MW. Incidence and implications of chemotherapy related hand-foot syndrome. Expert Opin Drug Saf. 2016;15:1625–33.

Article  CAS  PubMed  Google Scholar 

Pugalia N, Singh R, Madke B, Rusia K, Jaiswal S. Capecitabine-induced palmo-plantar erythrodysesthesia (toxic erythema of chemotherapy). Dermatol Online J. 2023; https://doi.org/10.5070/D329160225.

do Nascimento ADA, Porto DM, de L VAK. Capecitabine-induced oral mucosal hyperpigmentation associated with hand-foot syndrome – A literature review. An Bras Dermatol. 2023;98:302–9.

Article  PubMed  PubMed Central  Google Scholar 

Whorton AE, Razzak AN, Jha P. Hand-Foot Syndrome Presentation Post-Capecitabine Treatment in a Black Patient. Cureus. 2022; https://doi.org/10.7759/cureus.26891.

Huang J, Ye S, Feng S, Zheng M, Zhong M. Prevalence of hand-foot syndrome following chemotherapy for colorectal cancer: a systematic review and meta-analysis. Int J Color Dis. 2023;38:61.

Article  Google Scholar 

Pandy JGP, Franco PIG, Li RK. Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials. Support Care Cancer. 2022;30:8655–66.

PubMed  Google Scholar 

Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda®). Eur J Oncol Nurs. 2004;8:S31–40.

Article  PubMed  Google Scholar 

Kwakman JJM, Elshot YS, Punt CJA, Koopman M. Management of cytotoxic chemotherapy-induced hand-foot syndrome. Oncol Rev. 2020; https://doi.org/10.4081/oncol.2020.442.

Zhao J, Zhang X, Cui X, Wang D, Zhang B, Ban L. Loss of Fingerprints as a Side Effect of Capecitabine Therapy: Case Report and Literature Review. Oncol Res. 2020;28:103–6.

Article  PubMed  PubMed Central  Google Scholar 

Rzepecki AK, Franco L, McLellan BN. PATEO syndrome: periarticular thenar erythema with onycholysis. Acta Oncol. 2018;57:991–2.

Article  PubMed  Google Scholar 

Kaur J, Gaurav V, Tyagi M. Paclitaxel-Induced Periarticular Thenar Erythema with Onycholysis Syndrome. Skin Appendage Disord. 2024;10:74–7.

Article  PubMed  Google Scholar 

Charron-Ligez F, Désy D, Auclair M-H. Paclitaxel-induced periarticular thenar eminence erythema with onycholysis: A case report. SAGE Open Med Case Rep. 2023; https://doi.org/10.1177/2050313X231213930.

Chanprapaph K, Rutnin S, Vachiramon V. Multikinase Inhibitor-Induced Hand–Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management. Am J Clin Dermatol. 2016;17:387–402.

Article  PubMed  Google Scholar 

Shou L, Chen J, Shao T, Zhang Y, Zhao S, Chen S, Shu Q. Clinical characteristics, treatment outcomes, and prognosis in patients with MKIs-associated hand-foot skin reaction: a retrospective study. Support Care Cancer. 2023;31:375.

PubMed  Google Scholar 

Said JT, Singer S, Iannattone L, Sauder M, LeBoeuf NR. Outcomes of Acitretin Treatment for Refractory Multikinase Inhibitor–Induced Hand-Foot Skin Reaction. JAMA Dermatol. 2022;158:824.

Article  PubMed  PubMed Central  Google Scholar 

Lee Y-S, Jung YK, Kim JH, et al. Effect of urea cream on sorafenib-associated hand–foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study. Eur J Cancer. 2020;140:19–27.

Article  CAS  PubMed  Google Scholar 

Huang W-K, Hsu H-C, Yang T-S, Lu C-W, Pan Y-R, Wu C-E, Chung W-H, Hung S-I, Yeh C-N. Zinc supplementation decreased incidence of grade ≥2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial. J Am Acad Dermatol. 2024;90:368–9.

Article  CAS  PubMed  Google Scholar 

Lu C-W, Yeh C-N, Hsu H-C, Chen C-B, Yang T-S, Pan Y-R, Chung W-H, Hung S-I. Zinc supplementation is associated with improvement in hand-foot skin reaction in patients on vascular endothelial growth factor receptor-tyrosine kinase inhibitors: A cohort study. J Am Acad Dermatol. 2024;90:814–5.

Article  CAS  PubMed  Google Scholar 

Zhu Y, Zhang X, Lou X, Chen M, Luo P, He Q. Vascular endothelial growth factor (VEGF) antibody significantly increases the risk of hand–foot skin reaction to multikinase inhibitors (MKIs): A systematic literature review and meta-analysis. Clin Exp Pharmacol Physiol. 2018;45:659–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ding F, Liu B, Wang Y. Risk of hand-foot skin reaction associated with vascular endothelial growth factor–tyrosine kinase inhibitors: A meta-analysis of 57 randomized controlled trials involving 24,956 patients. J Am Acad Dermatol. 2020;83:788–96.

Article  CAS  PubMed  Google Scholar 

Nguyen GH, Camilleri MJ, Wetter DA. Characterization and Management of Amicrobial Pustulosis of the Folds, Aseptic Abscess Syndrome, Behçet Disease, Neutrophilic Eccrine Hidradenitis, and Pyostomatitis Vegetans−Pyodermatitis Vegetans. Dermatol Clin. 2024;42:231–45.

Article  CAS  PubMed  Google Scholar 

Nelson CA, Stephen S, Ashchyan HJ, James WD, Micheletti RG, Rosenbach M. Neutrophilic dermatoses. J Am Acad Dermatol. 2018;79:987–1006.

Article  PubMed  Google Scholar 

Agarwal A, Samal P, Mohapatra D, Kar BR. Neutrophilic Eccrine Hidradenitis Presenting in a Case of Acute Undifferentiated Leukemia Before Chemotherapy. Indian J Drugs Dermatol. 2021;7:97–8.